title: Routine use of continuous glucose monitoring in 10 501 people with diabetes mellitus.
abstract: OBJECTIVE
  To analyse blood glucose control according to continuous glucose monitoring use in data from the CareLink database, and to identify factors associated with continuation of sensor use during sensor-augmented pump therapy.
  
  
  METHODS
  The analysis used data from 10 501 people with Type 1 and 2 diabetes mellitus, of whom 7916 (61.7%) had used glucose sensors for ≥ 15 days during any 6-month period over a 2-year observation period. Data were analysed according to the extent of sensor use ( < 25%, 25-49%, 50-74% and ≥ 75% of the time). Time to discontinuation of sensor use was also analysed in new users of glucose sensors.
  
  
  RESULTS
  Compared with patients in the lowest sensor usage group and non-users, the highest glucose sensor usage group had significantly (P < 0.0001) lower mean blood glucose and blood glucose sd, were more likely to achieve a mean blood glucose concentration < 8.6 mmol/l, (odds ratio 1.5, 95% CI 1.3-1.7; P < 0.0001), and had 50% fewer hypoglycaemic (blood glucose concentration < 2.8 mmol/l) episodes. Among new users, sensor use during the first month of therapy was an important predictor of subsequent discontinuation. Lack of full reimbursement was also significantly associated with early discontinuation, whereas measures of glycaemic control were predictive of discontinuation during long-term treatment.
  
  
  CONCLUSIONS
  The use of continuous glucose monitoring was significantly associated with reductions in hypoglycaemia and improved metabolic control during insulin pump therapy. Sensor use during the first month was strongly associated with long-term adherence; patient education and training may be helpful in achieving this.
authors.affiliation: University Medical Centre Ljubljana, Ljubljana, Slovenia.|Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
authors.forename: T
authors.initials: T
authors.lastname: Battelino
authors.affiliation: Medtronic International Trading Sàrl, Tolochenaz, Switzerland.
authors.forename: S
authors.initials: S
authors.lastname: Liabat
authors.affiliation: Diabeter, Centre for Pediatric and Adolescent Diabetes Care and Research, Rotterdam, The Netherlands.
authors.forename: H J
authors.initials: HJ
authors.lastname: Veeze
authors.affiliation: Medtronic Bakken Research Center, Maastricht, The Netherlands.
authors.forename: J
authors.initials: J
authors.lastname: Castañeda
authors.affiliation: Medtronic Bakken Research Center, Maastricht, The Netherlands.
authors.forename: A
authors.initials: A
authors.lastname: Arrieta
authors.affiliation: Chaim Sheba Medical Centre, Ramat Gan, Israel.
authors.forename: O
authors.initials: O
authors.lastname: Cohen
mesh_terms: D001786:Blood Glucose / Q000032:analysis*; D002170:Canada; D015331:Cohort Studies; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000188:drug therapy / Q000191:economics; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy / Q000191:economics; D004351:Drug Resistance; D005060:Europe; D066275:Health Information Exchange; D006801:Humans; D006943:Hyperglycemia / Q000517:prevention & control*; D007003:Hypoglycemia / Q000139:chemically induced / Q000517:prevention & control*; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D007328:Insulin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D007332:Insulin Infusion Systems / Q000009:adverse effects; D007349:Insurance, Health, Reimbursement; D007557:Israel; D018670:Monitoring, Ambulatory / Q000191:economics; D010349:Patient Compliance; D010818:Practice Patterns, Physicians'; D013997:Time Factors
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin